Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Cushing Mlp & Infrastructure Total Return Fund | SRV | Sep 27, 2024 | 44.60 | -0.11 |
Cushman & Wakefield | CWK | Sep 27, 2024 | 13.65 | -1.09 |
Custom Truck One Source | CTOS | Sep 27, 2024 | 3.60 | +0.56 |
Customers Bancorp | CUBI | Sep 27, 2024 | 45.38 | +1.27 |
Customers Bancorp E Pref | CUBI-E | Sep 27, 2024 | 25.39 | 0.00 |
Customers Bancorp F Pref | CUBI-F | Sep 27, 2024 | 25.11 | +0.14 |
Cutera | CUTR | Sep 27, 2024 | 0.77 | +5.08 |
CVB Financial | CVBF | Sep 27, 2024 | 17.73 | +0.45 |
CVD Equipment | CVV | Sep 27, 2024 | 3.32 | +1.84 |
CVR Energy | CVI | Sep 27, 2024 | 23.15 | +0.92 |
Cvr Partners LP Unit | UAN | Sep 27, 2024 | 67.40 | -0.04 |
CVRx | CVRX | Sep 27, 2024 | 8.63 | +2.25 |
CVS Health | CVS | Sep 27, 2024 | 61.38 | +4.02 |
CXApp A | CXAI | Sep 27, 2024 | 1.71 | +6.88 |
CyberArk Software | CYBR | Sep 27, 2024 | 282.89 | -1.56 |
Cybin | CYBN | Sep 27, 2024 | 9.60 | -2.83 |
Cyclacel Pharmaceuticals | CYCC | Sep 27, 2024 | 1.03 | +3.00 |
Cyclacel Pharmaceuticals Pref | CYCCP | Sep 27, 2024 | 7.00 | 0.00 |
Cyclerion Therapeutics | CYCN | Sep 27, 2024 | 2.62 | -3.13 |
Cyclo Therapeutics | CYTH | Sep 27, 2024 | 0.72 | +2.86 |
Cyngn | CYN | Sep 27, 2024 | 3.85 | +3.77 |
Cytek Biosciences | CTKB | Sep 27, 2024 | 5.39 | +3.65 |
Cytokinetics | CYTK | Sep 27, 2024 | 52.34 | -0.55 |
Cytomed Therapeutics | GDTC | Sep 27, 2024 | 1.55 | +4.73 |
CytomX Therapeutics | CTMX | Sep 27, 2024 | 1.20 | 0.00 |
Cytosorbents | CTSO | Sep 27, 2024 | 1.50 | +5.63 |
D-MARKET Electronic Services & Trading ADR | HEPS | Sep 27, 2024 | 2.27 | +2.25 |
D-Wave Quantum | QBTS | Sep 27, 2024 | 1.03 | +5.09 |
D.R. Horton | DHI | Sep 27, 2024 | 190.35 | +1.24 |
Dada Nexus ADR | DADA | Sep 27, 2024 | 1.81 | +13.13 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.